A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, pharmacology.
Follow us to keep up to date.
The Most Read Articles of 2021: Pharmacology
01- Swan Ganz Associated with Better Outcomes in Cardiogenic Shock: Is It Back?
The Swan Ganz catheter has been used in the clinical practice for years. However, its usefulness remains under discussion and its use keeps dropping.
Read more HERE
02- Major Cause of Myocardial Injury by COVID-19
The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These microthrombi resulted quite different in composition vs. thrombi obtained from COVID-19 negative patients and thrombi obtained from infected patients with ACS.
Read more HERE
03- Post MI Betablockers for Good?
Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.
Read more HERE
04- ESC 2021 | GREENNESS: Surprising New Protective Factor against Cardiovascular Disease
What Is “Greenness”? This factor—which generally refers to the proximity to vegetation, as measured by satellite pictures—could serve as a new protection against cardiovascular disease.
Read more HERE
In patients at high bleeding risk with drug-eluting stents, the duration of dual antiplatelet therapy has been subjected to ongoing review. Guidelines from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) suggest shortening this treatment to a maximum of three to six months (Class IIb). The ESC establishes a difference depending on whether the condition is acute or chronic.
Read more HERE
06- The Best Anticoagulant Agent for AF After TAVR
Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after transcatheter aortic valve replacement (TAVR), compared with classic vitamin K antagonists.
Read more HERE
07- ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate
The results of the STEP study were presented at the European Society of Cardiology (ESC) 2021 Congress! The main finding from this research was that an ideal target of 110 mmHg or at least <130 mmHg blood pressure (compared with a target of 130 mmHg or at least 150 mmHg) yielded an absolute risk reduction of composite events of 1.1%
Read more HERE
Promising fast subcutaneous administration and a quick and potent antiplatelet effect, here comes a novel glycoprotein IIb/IIa inhibitor called RUC-4. This novel drug was tested in the CELEBRATE-02 study, presented at EuroPCR 2021 and simultaneously published in EuroIntervention.
Read more HERE
09- More Evidence for Short Term DAPT: Approaching “the Class Effect”
Patients at high risk of bleeding undergoing coronary angioplasty with Orsiro stent can be considered for a short dual antiplatelet scheme.
Read more HERE
10- HOST-EXAM: The Study that Challenges Aspirin as Long-Term Antiplatelet Therapy
The HOST-EXAM study (which was prospective, randomized, and open-label, with the participation of 37 Korean sites) was specifically designed to determine the role of aspirin as the long-term antiplatelet therapy of choice after angioplasty with current drug-eluting stents. To this end, the study compared aspirin head-to-head with clopidogrel.
Read more HERE
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
